Mult Scler Relat Disord 2021 May 30;53:103049. Epub 2021 May 30.
Centro de Esclerosis Múltiple de Buenos Aires, CABA; Argentina; Servicio de Neurología, Hospital Universitario CEMIC, Buenos Aires, Argentina.
We report COVID-19 presentation, course and outcomes in teriflunomide-treated MS patients in Argentina.
Methods: descriptive, retrospective, multicentre, study that included MS patients receiving teriflunomide who developed COVID-19, with clinical follow-up at reference MS centres, also listed in a nationwide registry.
Results: Eighteen MS patients on teriflunomide treatment, from eight MS centres developed COVID-19. Read More